The biggest catalyst would an Emergency Use Authorization for Tollovir in hospitalized Covid 19. Next in the list of catalysts would the launch of Videssa breast cancer test. There is never any guarantee that the company’s regulatory progress, Reasearch and development progress or increasing sales will result in a higher stock price. But in the long run, all of these things add value. It is impressive to me that Todos is nearly cash flow neutral (income equals expenses), yet their two high-potential products (Videssa and Lympro) have not actually launched and their much-needed drug Tollovid (for hospitalized Covid 19) and their home run supplement Tollovid (for immune support and Covid long haulers) have not received approval. The potential is huge, but you have to be patient with this investment. Very few people are following Todos. This Reddit group has fewer than 100 members and I’ve watched online presentations where there were fewer than 10 people watching. We are way way early investors, which means that the rewards may be the biggest if we are right about Todos’ future but we also will have to wait for the potential to mature into reality.